Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant liposomal doxorubicin plus pucotenlimab for undifferentiated pleomorphic sarcoma and myxofibrosarcoma
ChiCTR2400091168Phase 2Not yet recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Oct 2024
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin and pucotenlimab in Malignant Fibrous Histiocytoma (MFH) and myxofibrosarcoma (MFS), sponsored by Shanghai Changzheng Hospital. Primary endpoints: Objective response rate and Safety and tolerability. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
pegylated liposomal doxorubicinpucotenlimab
03
Conditions
Malignant Fibrous Histiocytoma (MFH)myxofibrosarcoma (MFS)
Beyond the preview
Go deeper on ChiCTR2400091168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091168.